CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

The Executive Director of the Ghana Foundation for Sickle Gene Action, Victoria Awo Twumasi, has appealed to President John Dramani Mahama to include full coverage of sickle cell disease (SCD) treatme ...

According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

SRT CEO Patrick Girondi and Artist and Project Manager Megan Euker with newly restored San Rocco sculpture, Altamura, Italy.

Panellists at a day’s conference to mark this year’s world sickle cell day have called for a fixed protocol for the treatment of sickle cell emergencies ...

Columnist Oluwatosin Adesoye, a doctor, sorts through the difference between sickle cell anemia and sickle cell disease — and more.

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best oversold NASDAQ stocks to buy now. On July 1, Beam Therapeutics Inc.